Coya Therapeutics Inc. (COYA)

AI Score

Unlock

7.69

0.61 (8.62%)

At close: Mar 03, 2025, 12:43 PM

No 1D chart data available

Bid	7.62
Market Cap	128.48M
Revenue (ttm)	10.49M
Net Income (ttm)	-11.74M
EPS (ttm)	-0.65
PE Ratio (ttm)	-11.83
Forward PE	-5.38
Analyst	Buy

Ask	7.81
Volume	199,653
Avg. Volume (20D)	76,294
Open	7.07
Previous Close	7.08
Day's Range	7.03 - 8.29
52-Week Range	4.75 - 10.69
Beta	0.48

About COYA

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial f...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 29, 2022

Employees 8

Stock Exchange NASDAQ

Ticker Symbol COYA

Website https://www.coyatherapeutics.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for COYA stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 114.56% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 weeks ago

+7.2%

Coya Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

4 months ago

-27.67%

Coya Therapeutics shares are trading lower. The company announced results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.

News

5 days ago · businesswire.com

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...

3 weeks ago · seekingalpha.com

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD

Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically com...

3 weeks ago · seekingalpha.com

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch

Potential initiation of phase 2b study using COYA-302 for the treatment of patients with Amyotrophic Lateral Sclerosis, expected in 2025 barring successful IND clearance by the FDA. Biomarker data fro...

3 weeks ago · benzinga.com

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

On Thursday, Coya Therapeutics, Inc. COYA announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients wit...